Conventional Synthetic Disease-modifying Drugs Remain the Mainstay of Therapy for Rheumatoid Arthritis in India
Cs-DMARDs remain the mainstay in the treatment of Indian patients with RA in this study, with the majority being treated with methotrexate alone or in combination with other DMARDs.
Authors
- Dr Jayesh Rawal
- Shahzeene Dhuria
- Varun Dhir (ORCID: https://orcid.org/0000-0002-3626-0694)
- Rajiva Gupta
- Padmanabha Shenoy (ORCID: https://orcid.org/0000-0002-7666-1361)
- Shery Susan Phillip
- Vineeta Shobha (ORCID: https://orcid.org/0000-0001-5271-0766)
- Amar Taksande (ORCID: https://orcid.org/0000-0003-3097-7405)
- Sanjay R. Jain (ORCID: https://orcid.org/0000-0002-0141-7655)
- Kuldeep Kumar
- Sandeep Kumar (ORCID: https://orcid.org/0000-0003-3440-3628)
- G. Singh (ORCID: https://orcid.org/0000-0002-5005-7078)
- Asha Bhagat
- Seehui Chiu
- Anuroopa Manovihar
- Chaitanya Soni
Institutions
- Medanta The Medicity (IN)
- Ahmedabad Civil Hospital (IN)
- Medanta The Medicity (IN)
- Arthritis and Rheumatism Associates (US)
- Post Graduate Institute of Medical Education and Research (IN)
Publication Details
- Journal
- Journal of the Association of Physicians of India
- Published
- 2024-12-01
- DOI
- https://doi.org/10.59556/japi.72.0756
- Citations
- 2
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.48